This article presents an economic evaluation of asthma in the United States, estimating the total cost of the illness in 1990 at $6.2 billion. The study analyzed direct medical expenditures and indirect costs, including lost productivity and mortality. Direct medical costs were primarily driven by inpatient hospitalizations, which accounted for nearly $1 billion, followed by medication costs at $712.7 million. Indirect costs, mainly from lost productivity, were the largest, with over $2 billion attributed to lost school and work days. Mortality costs were estimated at $676.2 million. The study used data from various national surveys to estimate the costs of asthma-related healthcare utilization, including hospitalizations, emergency room visits, outpatient care, and physician services. It also considered indirect costs such as lost productivity due to asthma-related school and work absences, as well as the economic impact of premature death. The findings indicate that asthma is a significant economic burden in the United States, with a large portion of costs attributed to inpatient care and lost productivity. The study highlights the importance of improving primary care for asthma to reduce hospitalizations and overall costs. It also notes that asthma-related costs are substantial, accounting for 8% of health expenditures and 10% of indirect costs for all respiratory diseases. The study emphasizes the need for effective interventions to reduce the economic burden of asthma, particularly through improvements in primary care and better management of the condition. The results suggest that focusing on primary care can lead to significant cost savings by reducing hospitalizations and improving overall health outcomes for individuals with asthma.This article presents an economic evaluation of asthma in the United States, estimating the total cost of the illness in 1990 at $6.2 billion. The study analyzed direct medical expenditures and indirect costs, including lost productivity and mortality. Direct medical costs were primarily driven by inpatient hospitalizations, which accounted for nearly $1 billion, followed by medication costs at $712.7 million. Indirect costs, mainly from lost productivity, were the largest, with over $2 billion attributed to lost school and work days. Mortality costs were estimated at $676.2 million. The study used data from various national surveys to estimate the costs of asthma-related healthcare utilization, including hospitalizations, emergency room visits, outpatient care, and physician services. It also considered indirect costs such as lost productivity due to asthma-related school and work absences, as well as the economic impact of premature death. The findings indicate that asthma is a significant economic burden in the United States, with a large portion of costs attributed to inpatient care and lost productivity. The study highlights the importance of improving primary care for asthma to reduce hospitalizations and overall costs. It also notes that asthma-related costs are substantial, accounting for 8% of health expenditures and 10% of indirect costs for all respiratory diseases. The study emphasizes the need for effective interventions to reduce the economic burden of asthma, particularly through improvements in primary care and better management of the condition. The results suggest that focusing on primary care can lead to significant cost savings by reducing hospitalizations and improving overall health outcomes for individuals with asthma.